‘Significant Discounts’ For Biosimilars Could Disrupt US Market
Pacific Research Institute Report Urges Removal Of Barriers To Price Competition
With the launch of rivals to Humira looming in 2023, removing barriers to free pricing and reforming formularies will be essential to promote biosimilar competition in the US, according to Wayne Winegarden of the Pacific Research Institute.
You may also be interested in...
The US Association for Accessible Medicines’ annual report into generic and biosimilar savings has documented another year of increased cost savings thanks to off-patent drugs, but says some patients are still overpaying for their generic medicines.
The AAM has criticized the passage of the US Inflation Reduction Act though the country’s Senate, claiming that the legislation’s “flawed framework for government price setting” will chill generic and biosimilar development and will reduce patient access.
Ahead of the first biosimilar Humira product set to launch in 365 days, Generics Bulletin provides a comprehensive run-down of where biosimilar sponsors stand and the key issues ahead of market formation.